Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1989-1-5
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0036-5548
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
457
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:3194716-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:3194716-Female,
pubmed-meshheading:3194716-Heparin,
pubmed-meshheading:3194716-Hepatitis B,
pubmed-meshheading:3194716-Humans,
pubmed-meshheading:3194716-Injections, Subcutaneous,
pubmed-meshheading:3194716-Substance-Related Disorders,
pubmed-meshheading:3194716-Thrombophlebitis
|
pubmed:year |
1988
|
pubmed:articleTitle |
Subcutaneous calcium heparin for anticoagulation of HIV/hepatitis B infected intravenous drug abusers.
|
pubmed:publicationType |
Letter
|